NovaBridge Biosciences
NASDAQ: NBP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Xi-Yong Fu
- Employees
- 32
- Headquarters
- Rockville, United States
- IPO year
- 2020
- Market cap
- $184.4M
- Website
- https://www.i-mabbiopharma.com
Loading NBP…
Loading profile data…Frequently asked questions about NBP
What does NovaBridge Biosciences (NBP) do?
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing...
Where does NBP trade?
NovaBridge Biosciences (NBP) trades on the NASDAQ Global Market.
What sector is NBP in?
NovaBridge Biosciences (NBP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NovaBridge Biosciences?
Xi-Yong Fu is the chief executive officer of NovaBridge Biosciences (NBP).
Where is NovaBridge Biosciences headquartered?
NovaBridge Biosciences is headquartered in United States.
Does NBP pay a dividend?
NovaBridge Biosciences (NBP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NBP go public?
NovaBridge Biosciences (NBP) completed its initial public offering in 2020.
Is NBP an ADR?
Yes — NBP is an American Depositary Receipt; its underlying shares trade on a non-US exchange. NovaBridge Biosciences reporting and dividends follow the underlying issuer.